awmsg logo



afatinib (Giotrif®)


Reference No. 1720

Publication date:
27/07/2016


Appraisal information

afatinib (Giotrif®) 20 mg film-coated tablet
afatinib (Giotrif®) 30 mg film-coated tablet
afatinib (Giotrif®) 40 mg film-coated tablet
afatinib (Giotrif®) 50 mg film-coated tablet


Company: Boehringer Ingelheim Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 26/07/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, afatinib (Giotrif®) cannot be endorsed for use within NHS Wales for the treatment of locally advanced or metastatic non-small cell lung cancer of squamous histology progressing on or after platinum-based chemotherapy.
Statement of Advice (SOA)
Download